RIGEL PHARMACEUTICALS INC EVP and Chief Medical Officer Lisa Rojkjaer reported a tax-related share disposition. On June 1, 2026, 850 shares of Common Stock were transferred at $29.86 per share to cover an exercise price or tax liability by delivering securities.
After this transaction, she directly owned 34,003 shares of Rigel common stock. The filing reflects a tax-withholding disposition rather than an open-market purchase or sale.
RIGEL PHARMACEUTICALS INC CEO and President Raul R. Rodriguez reported a Form 4 transaction involving a tax-related share disposition. On June 1, 2026, 2,424 shares of Common Stock were delivered at $29.86 per share to satisfy tax obligations. After this transaction, Rodriguez directly holds 279,593 shares of Common Stock, indicating the event reflects routine tax withholding rather than an open-market trade.
RIGEL PHARMACEUTICALS INC executive Raymond J. Furey reported a small tax-related share disposition. On June 1, 2026, 877 shares of common stock were delivered at $29.86 per share to cover tax obligations, a non‑market transaction classified as a tax-withholding disposition. Following this, he directly holds 50,936 common shares, indicating the adjustment is minor relative to his remaining position.
RIGEL PHARMACEUTICALS INC director Ali-Jackson Kamil reported an open-market sale of 2,500 shares of Common Stock on May 26, 2026, at an average price of $29.17 per share. Following the sale, the director directly holds 12,625 shares. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Rigel Pharmaceuticals reported results from its 2026 annual stockholder meeting. Stockholders approved amendments to the 2018 Equity Incentive Plan and the 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares of common stock, respectively, for future equity grants and purchases.
All three director nominees were elected to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, executive compensation as described in the proxy statement and ratified Ernst & Young LLP as Rigel’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Wasman Jane reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Jane Wasman received an equity grant of 5,750 shares of Common Stock. The award is structured as Restricted Stock Units that will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues serving on the Board of Directors.
Following this grant, her direct holdings increase to 18,250 shares, reflecting routine, compensation-related equity rather than an open-market stock purchase.
RIGEL PHARMACEUTICALS INC director Walter H. Moos received an equity award. On 2026-05-15, he was granted 5,750 shares of Common Stock at a grant price of $0.00 per share through a Restricted Stock Unit (RSU) award.
The footnote states these shares will be acquired only when the RSUs fully vest on the date prior to the company’s next Annual Meeting, as long as he continues serving on the Board of Directors. After this award, his direct holdings are 18,472 Common Stock shares.
MILLER MICHAEL PATRICK reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Michael Patrick Miller reported an equity grant of 5,750 shares of Common Stock via Restricted Stock Units. The award has a grant price of $0.00 per share because it is a compensation grant, not a market purchase.
According to the footnote, these Restricted Stock Units will fully vest on the date prior to the company’s next Annual Meeting, as long as Miller continues serving on the Board of Directors. After this grant, he holds 5,937 shares of Common Stock directly.
LAPOINTE ANTHONY GREGG reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Anthony Gregg Lapointe reported an equity compensation grant of 5,750 shares of Common Stock, recorded at a price of $0.00 per share. These shares are tied to a Restricted Stock Unit award that will fully vest on the date prior to the company’s next Annual Meeting, if he continues serving on the Board of Directors. Following this award, Lapointe’s reported direct holdings total 18,250 shares of Common Stock.